Internal medicine journal
-
Internal medicine journal · Sep 2020
Multicenter StudyTocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study.
Interstitial lung disease (ILD) is the most severe extra-articular manifestation of rheumatoid arthritis (RA). Although it is responsible of 10-20% of all RA mortality, no controlled studies are available for the treatment of RA-ILD and its therapeutic approach is still debated. ⋯ The management of RA-ILD patients remains a critical unmet need. TCZ demonstrated a good safety profile in patients with RA-ILD and a potential effect on the stabilisation of lung involvement.
-
Internal medicine journal · Sep 2020
Bortezomib use and outcomes for the treatment of multiple myeloma.
The public subsidy in Australia of bortezomib (Velcade) for untreated non-transplant multiple myeloma patients was based on the VISTA trial. ⋯ Our patients were older, had worse disease characteristics and more comorbidities than patients in the VISTA trial. While response rates were similar, survival outcomes appeared worse. Bortezomib-based treatment in the real world setting still carries a high risk of toxicity in the elderly population.